Management of Epigenomic Networks Entailed in Coronavirus Infections and COVID-19

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2020 Aug 8

PMID 32758273

Citations 34

Authors

Ranim El Baba

Georges Herbein

Affiliations

Soon will be listed here.

Abstract

Coronaviruses (CoVs) are highly diverse single-stranded RNA viruses owing to their susceptibility to numerous genomic mutations and recombination. Such viruses involve human and animal pathogens including the etiologic agents of acute respiratory tract illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the highly morbific SARS-CoV-2. Coronavirus disease 2019 (COVID-19), an emerging disease with a quick rise in infected cases and deaths, was recently identified causing a worldwide pandemic. COVID-19 disease outcomes were found to increase in elderly and patients with a compromised immune system. Evidences indicated that the main culprit behind COVID-19 deaths is the cytokine storm, which is illustrated by an uncontrolled over-production of soluble markers of inflammation. The regulation process of coronavirus pathogenesis through molecular mechanism comprise virus-host interactions linked to viral entry, replication and transcription, escape, and immune system control. Recognizing coronavirus infections and COVID-19 through epigenetics lens will lead to potential alteration in gene expression thus limiting coronavirus infections. Focusing on epigenetic therapies reaching clinical trials, clinically approved epigenetic-targeted agents, and combination therapy of antivirals and epigenetic drugs is currently considered an effective and valuable approach for viral replication and inflammatory overdrive control.

Citing Articles

Bioinformatics Insights on Viral Gene Expression Transactivation: From HIV-1 to SARS-CoV-2.

Patarca R, Haseltine W Int J Mol Sci. 2024; 25(6).

PMID: 38542351 PMC: 10970485. DOI: 10.3390/ijms25063378.

Plant-Derived Epi-Nutraceuticals as Potential Broad-Spectrum Anti-Viral Agents.

Gabbianelli R, Shahar E, de Simone G, Rucci C, Bordoni L, Feliziani G Nutrients. 2023; 15(22).

PMID: 38004113 PMC: 10675658. DOI: 10.3390/nu15224719.

Comprehensive DNA methylation profiling of COVID-19 and hepatocellular carcinoma to identify common pathogenesis and potential therapeutic targets.

Luo H, Chen J, Jiang Q, Yu Y, Yang M, Luo Y Clin Epigenetics. 2023; 15(1):100.

PMID: 37309005 PMC: 10259366. DOI: 10.1186/s13148-023-01515-8.

A review of cytokine-based pathophysiology of Long COVID symptoms.

Low R, Low R, Akrami A Front Med (Lausanne). 2023; 10:1011936.

PMID: 37064029 PMC: 10103649. DOI: 10.3389/fmed.2023.1011936.

Epigenetic Targets and Pathways Linked to SARS-CoV-2 Infection and Pathology.

Rabaan A, Aljeldah M, Al Shammari B, Alsubki R, Alotaibi J, Alhashem Y Microorganisms. 2023; 11(2).

PMID: 36838306 PMC: 9967649. DOI: 10.3390/microorganisms11020341.

References

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Wang J, Li G, Ming S, Wang C, Shi L, Su B . BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses. PLoS Pathog. 2020; 16(3):e1008429. PMC: 7122826. DOI: 10.1371/journal.ppat.1008429. View

Li X, Yang H, Huang S, Qiu Y . Histone deacetylase 1 and p300 can directly associate with chromatin and compete for binding in a mutually exclusive manner. PLoS One. 2014; 9(4):e94523. PMC: 3983199. DOI: 10.1371/journal.pone.0094523. View

Zaborowska J, Isa N, Murphy S . P-TEFb goes viral. Bioessays. 2016; 38 Suppl 1:S75-85. DOI: 10.1002/bies.201670912. View

Lau S, Fan R, Luk H, Zhu L, Fung J, Li K . Replication of MERS and SARS coronaviruses in bat cells offers insights to their ancestral origins. Emerg Microbes Infect. 2018; 7(1):209. PMC: 6286955. DOI: 10.1038/s41426-018-0208-9. View

Principi N, Esposito S . Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020; 20(10):1118. PMC: 7164862. DOI: 10.1016/S1473-3099(20)30296-6. View

Kim E, Erdos G, Huang S, Kenniston T, Balmert S, Donahue Carey C . Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:102743. PMC: 7128973. DOI: 10.1016/j.ebiom.2020.102743. View

Dekker F, van den Bosch T, Martin N . Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases. Drug Discov Today. 2013; 19(5):654-60. DOI: 10.1016/j.drudis.2013.11.012. View

Cheng V, Lau S, Woo P, Yuen K . Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007; 20(4):660-94. PMC: 2176051. DOI: 10.1128/CMR.00023-07. View

10.

Devaux C, Rolain J, Raoult D . ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020; 53(3):425-435. PMC: 7201239. DOI: 10.1016/j.jmii.2020.04.015. View

11.

Yang T, Li S, Zhang X, Pang X, Lin Q, Cao J . Resveratrol, sirtuins, and viruses. Rev Med Virol. 2015; 25(6):431-45. DOI: 10.1002/rmv.1858. View

12.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

13.

Herbein G, Wendling D . Histone deacetylases in viral infections. Clin Epigenetics. 2012; 1(1-2):13-24. PMC: 3365363. DOI: 10.1007/s13148-010-0003-5. View

14.

Larsson L, Thorbert-Mros S, Rymo L, Berglundh T . Influence of epigenetic modifications of the interleukin-10 promoter on IL10 gene expression. Eur J Oral Sci. 2012; 120(1):14-20. DOI: 10.1111/j.1600-0722.2011.00917.x. View

15.

Koyuncu E, Budayeva H, Miteva Y, Ricci D, Silhavy T, Shenk T . Sirtuins are evolutionarily conserved viral restriction factors. mBio. 2014; 5(6). PMC: 4271551. DOI: 10.1128/mBio.02249-14. View

16.

Ait-Ammar A, Kula A, Darcis G, Verdikt R, De Wit S, Gautier V . Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. Front Microbiol. 2020; 10:3060. PMC: 6993040. DOI: 10.3389/fmicb.2019.03060. View

17.

Poppe M, Wittig S, Jurida L, Bartkuhn M, Wilhelm J, Muller H . The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog. 2017; 13(3):e1006286. PMC: 5386326. DOI: 10.1371/journal.ppat.1006286. View

18.

Yang F, Zhou S, Wang C, Huang Y, Li H, Wang Y . Epigenetic modifications of interleukin-6 in synovial fibroblasts from osteoarthritis patients. Sci Rep. 2017; 7:43592. PMC: 5337936. DOI: 10.1038/srep43592. View

19.

Shereen M, Khan S, Kazmi A, Bashir N, Siddique R . COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020; 24:91-98. PMC: 7113610. DOI: 10.1016/j.jare.2020.03.005. View

20.

Pinto B, Oliveira A, Singh Y, Jimenez L, Goncalves A, Ogava R . ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. J Infect Dis. 2020; 222(4):556-563. PMC: 7377288. DOI: 10.1093/infdis/jiaa332. View